Starting from the concept that immunotherapy is certainly one of the last frontiers in the treatment of cancer, in the work of Daga et al. [114], a mouse orthotopic model of glioma was studied using either genetically modified IL-21 or recombinant IL-21 cells as the treatment. The gene discussed is IL21; the disease is central nervous system cancer.